市場調查報告書
商品編碼
1471950
近距離放射治療設備市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍:按產品類型、類型、應用、最終用戶和地理位置Brachytherapy Devices Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Type, Application, End User, and Geography |
近距離治療設備市場預測可以幫助該市場的利害關係人規劃其成長策略。該市場預計將從2022年的3.1096億美元成長到2030年的5.0175億美元;預計 2022 年至 2030 年複合年成長率為 6.2%。
近距離放射治療是一種用於治療癌症的放射治療形式。它涉及將放射性材料放入患者體內,以向受影響的區域提供高劑量的輻射。有兩種類型的近距離放射治療技術 - 低劑量率 (LDR) 和高劑量率 (HDR),這兩種技術通常用於治療前列腺癌。全球癌症盛行率的不斷上升預計將促進近距離放射治療的採用。此外,近距離放射治療相對於傳統治療方法的優勢,例如更短的治療時間、更高的有效性以及近距離放射治療設備的進步,可能會推動全球近距離放射治療設備市場的成長。
影響近距離放射治療設備市場的因素
近十年來,近距離放射治療取得了重大進展,這要歸功於治療器、影像、治療計劃和臨床試驗的改進。此外,目前近距離放射治療技術的研究不斷改變這種治療方式的實施方式。將近距離放射治療與其他治療方法(例如外部放射治療、化療、免疫治療或手術)相結合已成為癌症治療的一個有前景的趨勢。例如,2021年8月《當代近距離放射治療雜誌》發表的一篇文章中,開展了癌症聯合治療、腫瘤致敏和正常組織保護、分子放射生物學以及近距離放射治療臨床研究等方面的研究。結論是,近距離放射治療與免疫治療相結合可以改善局部腫瘤控制並增強未照射病灶的反應。
因此,近距離放射治療設備和治療的此類進步預計將在預測期內推動市場發展。
基於細分市場佔有率的近距離放射治療設備市場分析:
近距離放射治療設備市場依產品類型分為種子、近距離放射治療後裝機和施藥器以及電子近距離放射治療。近距離放射治療後裝置和給藥器細分市場在 2022 年佔據最大的市場佔有率,預計 2022 年至 2030 年複合年成長率最高。
市場根據類型分為高劑量率近距離治療植入物和低劑量率近距離治療植入物。低劑量率近距離放射治療植入物細分市場將在 2022 年佔據更大的近距離放射治療設備市場佔有率,預計 2022 年至 2030 年將以更快的複合年成長率成長。
近距離治療設備市場依應用分為乳癌、子宮頸癌、攝護腺癌、肺癌等。前列腺癌細分市場在 2022 年佔據最大市場佔有率,預計 2022-2030 年複合年成長率最高。
就最終用戶而言,市場分為醫院和專科診所、門診手術中心等。到 2022 年,醫院細分市場佔據最大的市場佔有率。
區域近距離放射治療設備市場分析:
從地理上看,全球近距離治療設備市場分為北美、亞太地區、歐洲、中東和非洲以及南美洲和中美洲。從收入來看,2022年北美在近距離治療設備市場佔有率中佔據主導地位。這可歸因於該地區女性乳癌和男性前列腺癌病例不斷增加等因素。根據泛美衛生組織 (PAHO) 統計,2020 年,美洲估計有 400 萬人被診斷出罹患癌症,預計到 2040 年這一數字將增加約 60%。
此外,BD、Isoray Inc. 和 Elekta 等市場參與者的存在以及先進近距離放射治療設備的可用性為市場擴張提供了巨大的機會。例如,2021 年 7 月,GenesisCare 透過從 Elekta 採購 27 套 Flexitron 近距離治療後裝系統和服務協議,擴大了近距離治療服務。這些先進的癌症治療設備使 GenesisCare 能夠跟上最新技術,並為其位於美國的中心的患者提供高品質的護理。
註 - 將為以下提到的地區/國家提供類似的分析
The brachytherapy devices market forecast can help stakeholders in this marketplace plan their growth strategies. The market is projected to grow from US$ 310.96 million in 2022 to US$ 501.75 million by 2030; it is projected to register a CAGR of 6.2% during 2022-2030.
Brachytherapy is a form of radiation treatment used to treat cancer. It involves placing radioactive materials inside the patient's body to deliver high doses of radiation to the affected areas. There are two types of brachytherapy techniques available - Low Dose Rate (LDR) and High Dose Rate (HDR), both of which are commonly used to treat prostate cancer. The increasing prevalence of cancer worldwide is expected to boost the adoption of brachytherapy treatment. Additionally, the advantages of brachytherapy over traditional treatment methods, such as shorter treatment times, greater effectiveness, and advancement in brachytherapy devices, are likely to drive growth in the global brachytherapy devices market.
Factors Affecting Brachytherapy Therapy Devices Market
Brachytherapy has undergone significant advancements in the last decade, attributed to improved applicators, imaging, treatment planning, and clinical trials. Moreover, the current research on brachytherapy technology continuously changes how this treatment modality is delivered. Combining brachytherapy with other treatments, such as external radiation therapy, chemotherapy, immunotherapy, or surgery, has become a promising trend in cancer management. For instance, in an article published by the Journal of Contemporary Brachytherapy in August 2021, studies on cancer treatment through combined modality, tumor sensitization and normal tissue protection, molecular radiation biology, and clinical investigations of brachytherapy were conducted. It was concluded that combining brachytherapy with immunotherapy can improve local tumor control and enhance non-irradiated lesion responses.
Therefore, such advancements in brachytherapy devices and treatments are anticipated to fuel the market during the forecast period.
Brachytherapy Therapy Devices Market Analysis Based on the Segmental Share:
The brachytherapy therapy devices market, by product type, is segmented into seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy. The brachytherapy afterloaders and applicators segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030.
The market is bifurcated based on type into high-dose rate brachytherapy implant and low-dose rate brachytherapy implant. The low-dose rate brachytherapy implant segment held a larger brachytherapy devices market share in 2022 and is anticipated to grow at a faster CAGR from 2022 to 2030.
The brachytherapy devices market, by application, is segmented into breast cancer, cervical cancer, prostate cancer, lung cancer, and others. The prostate cancer segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022-2030.
In terms of end user, the market is segmented into hospitals and specialty clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022. This can be attributed to the availability of better facilities and skilled physicians in hospitals over other surgical centers to perform minimally invasive procedures.
Regional Brachytherapy Therapy Devices Market Analysis:
Geographically, the global brachytherapy devices market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. In terms of revenue, North America dominated the brachytherapy devices market share in 2022. The brachytherapy devices market in this region is dominated by the US. This can be attributed to factors such as the increasing cases of breast cancer among women and prostate cancer among men in the region. According to the Pan America Health Organization (PAHO), in 2020, an estimated 4 million people in the Americas were diagnosed with cancer, which is predicted to increase by ~60% by 2040.
Additionally, the presence of market players, such as BD, Isoray Inc., and Elekta, and the availability of advanced brachytherapy devices present a sizable opportunity for market expansion. For instance, in July 2021, GenesisCare expanded its brachytherapy service by procuring 27 Flexitron brachytherapy afterloader systems and service agreements from Elekta. These advanced cancer treatment devices enabled GenesisCare to keep up with the latest technology and provide high-quality care to its patients across their centers in the US.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies